Uganda’s sickle cell breakthrough
Quality Chemical Industries Limited (QCIL) launched a locally manufactured version of Hydroxyurea in Uganda on 20 May, aiming to improve access, reduce costs, and boost pharmaceutical independence for sickle cell disease treatment. The condition affects an estimated 20,000 newborns annually in Uganda, with 30% of the population carrying the sickle cell gene, and the drug is expected to address long-standing supply and affordability challenges.
Uganda’s Quality Chemical Industries Limited (QCIL) launched a locally produced version of Hydroxyurea on 20 May at its Luzira facility in Kampala, marking a milestone in sickle cell disease treatment. The event, attended by government officials including the Ministry of Health and QCIL’s executive chairman Emmanuel Katongole, highlights the drug’s potential to improve access, lower costs, and strengthen Uganda’s pharmaceutical independence. Sickle cell disease is a major health burden in Uganda, with 20,000 babies born with the condition annually and 30% of the population carrying the sickle cell gene. The disease causes recurrent pain crises, frequent hospitalizations, anemia, and organ damage, disproportionately affecting families in northern, eastern, and central Uganda where specialized care is limited. Hydroxyurea, a globally recognized treatment, reduces painful crises, hospital admissions, and transfusion needs, though it has not been a cure. Until now, Uganda relied on imports, leading to inconsistent availability and high costs for patients. Local production aims to resolve these challenges by ensuring reliable and affordable treatment. QCIL, which has produced medicines for HIV and malaria for over two decades, is expanding into non-communicable and inherited conditions. CEO Ajay Kumar described the development as part of a broader push for African-led health solutions, emphasizing self-sufficiency and addressing local health needs. The launch aligns with Uganda’s broader strategy to strengthen domestic pharmaceutical manufacturing to tackle public health challenges. Experts view it as a step toward reducing dependency on imports and improving long-term healthcare outcomes for sickle cell patients.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.